Insilico caps year of deals by opening its computational platforms to pharmas’ in-house teams

Coming off a string of deals to discover targets and compounds on its partners’ behalf, Insilico Medicine has launched versions of its platforms that pharmas can use themselves.

This year, Insilico Medicine Inc. made its molecular target and small molecule discovery platforms, respectively dubbed Pandaomics and Chemistry42, available as software that drug developers can adopt in-house. ...